|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM112645143 |
| 003 |
DE-627 |
| 005 |
20231222162208.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0376.xml
|
| 035 |
|
|
|a (DE-627)NLM112645143
|
| 035 |
|
|
|a (NLM)11358434
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ichiyama, T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.06.2001
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a Kawasaki disease (KD) is a febrile disease of childhood characterized by systemic vasculitis, and the levels of many proinflammatory cytokines are elevated in the serum at the acute stage. We investigated the activation of transcription factor NF-kappaB for genes that encode the proinflammatory cytokines in CD14+ monocytes/macrophages and CD3+ T cells in peripheral blood by means of Western blot and flow cytometric analyses. Western blot analysis demonstrated that NF-kappaB activation was more increased in CD14+ monocytes/macrophages than in CD3+ T cells in all children during the acute stage. Flow cytometric analysis revealed that NF-kappaB activation in CD14+ monocytes/macrophages was significantly higher than in CD3+ T cells at the acute stage (30.0 +/- 16.0% vs 11.4 +/- 5.0%, P < 0.01, Wilcoxon test). NF-kappaB activation in CD14+ monocytes/macrophages was significantly decreased after high-dose intravenous immunoglobulin therapy (P < 0.05). The present findings suggest that CD14+ monocytes/macrophages play an important role in cytokine production during acute KD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 650 |
|
7 |
|a Lipopolysaccharide Receptors
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a C-Reactive Protein
|2 NLM
|
| 650 |
|
7 |
|a 9007-41-4
|2 NLM
|
| 700 |
1 |
|
|a Yoshitomi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishikawa, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujiwara, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matsubara, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayashi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Furukawa, S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 99(2001), 3 vom: 06. Juni, Seite 373-7
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:99
|g year:2001
|g number:3
|g day:06
|g month:06
|g pages:373-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 99
|j 2001
|e 3
|b 06
|c 06
|h 373-7
|